AMRX Relative Valuation
AMRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMRX is overvalued; if below, it's undervalued.
Historical Valuation
Amneal Pharmaceuticals Inc (AMRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 14.38 is considered Undervalued compared with the five-year average of 7.89. The fair price of Amneal Pharmaceuticals Inc (AMRX) is between 12.43 to 17.04 according to relative valuation methord. Compared to the current price of 12.18 USD , Amneal Pharmaceuticals Inc is Undervalued By 2.04%.
Relative Value
Fair Zone
12.43-17.04
Current Price：12.18
2.04%
Undervalued
14.10
PE
1Y
3Y
5Y
Trailing
Forward
9.23
EV/EBITDA
Amneal Pharmaceuticals Inc. (AMRX) has a current EV/EBITDA of 9.23. The 5-year average EV/EBITDA is 6.81. The thresholds are as follows: Strongly Undervalued below 4.68, Undervalued between 4.68 and 5.75, Fairly Valued between 7.88 and 5.75, Overvalued between 7.88 and 8.94, and Strongly Overvalued above 8.94. The current Forward EV/EBITDA of 9.23 falls within the Strongly Overvalued range.
10.03
EV/EBIT
Amneal Pharmaceuticals Inc. (AMRX) has a current EV/EBIT of 10.03. The 5-year average EV/EBIT is 7.86. The thresholds are as follows: Strongly Undervalued below 5.76, Undervalued between 5.76 and 6.81, Fairly Valued between 8.90 and 6.81, Overvalued between 8.90 and 9.95, and Strongly Overvalued above 9.95. The current Forward EV/EBIT of 10.03 falls within the Strongly Overvalued range.
1.22
PS
Amneal Pharmaceuticals Inc. (AMRX) has a current PS of 1.22. The 5-year average PS is 0.49. The thresholds are as follows: Strongly Undervalued below -0.12, Undervalued between -0.12 and 0.19, Fairly Valued between 0.80 and 0.19, Overvalued between 0.80 and 1.10, and Strongly Overvalued above 1.10. The current Forward PS of 1.22 falls within the Strongly Overvalued range.
13.05
P/OCF
Amneal Pharmaceuticals Inc. (AMRX) has a current P/OCF of 13.05. The 5-year average P/OCF is 4.30. The thresholds are as follows: Strongly Undervalued below -1.67, Undervalued between -1.67 and 1.32, Fairly Valued between 7.29 and 1.32, Overvalued between 7.29 and 10.27, and Strongly Overvalued above 10.27. The current Forward P/OCF of 13.05 falls within the Strongly Overvalued range.
19.80
P/FCF
Amneal Pharmaceuticals Inc. (AMRX) has a current P/FCF of 19.80. The 5-year average P/FCF is 4.80. The thresholds are as follows: Strongly Undervalued below -3.72, Undervalued between -3.72 and 0.54, Fairly Valued between 9.07 and 0.54, Overvalued between 9.07 and 13.33, and Strongly Overvalued above 13.33. The current Forward P/FCF of 19.80 falls within the Strongly Overvalued range.
Amneal Pharmaceuticals Inc (AMRX) has a current Price-to-Book (P/B) ratio of -34.98. Compared to its 3-year average P/B ratio of -8.81 , the current P/B ratio is approximately 296.90% higher. Relative to its 5-year average P/B ratio of -4.45, the current P/B ratio is about 685.65% higher. Amneal Pharmaceuticals Inc (AMRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 12.20%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 19.99% , the current FCF yield is about -100.00% lower.
-34.29
P/B
Median3y
-8.81
Median5y
-4.45
6.52
FCF Yield
Median3y
12.20
Median5y
19.99
Competitors Valuation Multiple
The average P/S ratio for AMRX's competitors is 0.00, providing a benchmark for relative valuation. Amneal Pharmaceuticals Inc Corp (AMRX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 11.68%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AMRX increased by 50.76% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 1.67 to 2.31.
The secondary factor is the Revenue Growth, contributed 11.68%to the performance.
Overall, the performance of AMRX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Amneal Pharmaceuticals Inc (AMRX) currently overvalued or undervalued?
What is Amneal Pharmaceuticals Inc (AMRX) fair value?
How does AMRX's valuation metrics compare to the industry average?
What is the current P/B ratio for Amneal Pharmaceuticals Inc (AMRX) as of Dec 05 2025?
What is the current FCF Yield for Amneal Pharmaceuticals Inc (AMRX) as of Dec 05 2025?
What is the current Forward P/E ratio for Amneal Pharmaceuticals Inc (AMRX) as of Dec 05 2025?